GLTO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

0.000

-100%

0.000

-100%

Estimates Revision

The market is revising No Change the revenue expectations for Galecto, Inc. (GLTO) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 89.11%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+89.11%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast GLTO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLTO is 32.00 USD with a low forecast of 32.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

32.00

Averages

32.00

High

32.00

Current: 0.000

Low

32.00

Averages

32.00

High

32.00

Leerink

Outperform

initiated

$46

2026-01-07

New

Reason

Leerink

Price Target

$46

2026-01-07

New

initiated

Outperform

Reason

Leerink initiated coverage of Galecto with an Outperform rating and $46 price target. In a reverse merger, Galecto acquired Damora Therapeutics to advance a pipeline targeting hematological cancers, including mutant calreticulin-(mCALR)-driven myeloproliferative neoplasms, important mutations driving pathology in essential thrombocythemia and myelofibrosis. The firm thinks lead asset DMR-001 has the potential to be a best-in-class agent for mCALR-driven MPNs, including patients with Type 1 and Type 2 mCALR mutations. Importantly, central to Leerink's investment thesis is the disease-modifying mechanism of action for mCALR agents, which could meaningfully expand the market. It forecasts DMR-001 could generate peak sales of $3.3B in MF and $3B in ET, which represents $21/share and $19/share in the firm's valuation model, respectively.

Guggenheim

Buy

maintain

$32 -> $36

2025-12-08

Reason

Guggenheim

Price Target

$32 -> $36

2025-12-08

maintain

Buy

Reason

Guggenheim raised the firm's price target on Galecto (GLTO) to $36 from $32 and keeps a Buy rating on the shares. The firm considers the ASH medical meeting "a positive development" because Incyte (INCY) reported INCA033989 data that de-risk the class for myelofibrosis, but showed a probability that efficacy in Type 2 patients has "been left on the table as a competitive opening" for DMR-001, the analyst tells investors.

Guggenheim

NULL -> Buy

initiated

$32

2025-11-30

Reason

Guggenheim

Price Target

$32

2025-11-30

initiated

NULL -> Buy

Reason

Guggenheim initiated coverage of Galecto with a Buy rating and $32 price target.

Valuation Metrics

The current forward P/E ratio for Galecto Inc (GLTO.O) is 0.00, compared to its 5-year average forward P/E of -1.07. For a more detailed relative valuation and DCF analysis to assess Galecto Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.07

Current PE

0.00

Overvalued PE

0.01

Undervalued PE

-2.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.03

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.48

Undervalued EV/EBITDA

-1.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

9.97

Current PS

0.00

Overvalued PS

37.00

Undervalued PS

-17.07

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 503.37% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 503.37% over the last month.

Sold

Bought

GLTO News & Events

Events Timeline

No data

News

5.0

01-06Globenewswire

Galecto Appoints New Executives to Advance DMR-001 Clinical Trials

2.0

2025-12-26Benzinga

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%

5.0

2025-12-16Globenewswire

Galecto Grants 312,535 Stock Options to New Employee

People Also Watch

Frequently Asked Questions

What is Galecto Inc (GLTO) stock price today?

The current price of GLTO is 20.07 USD — it has decreased -4.43 % in the last trading day.

What is Galecto Inc (GLTO)'s business?

Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.

What is the price predicton of GLTO Stock?

What is Galecto Inc (GLTO)'s revenue for the last quarter?

Galecto Inc revenue for the last quarter amounts to -3.16M USD, decreased -17.81 % YoY.

What is Galecto Inc (GLTO)'s earnings per share (EPS) for the last quarter?

Galecto Inc. EPS for the last quarter amounts to -2616000.00 USD, decreased -28.35 % YoY.

What changes have occurred in the market's expectations for Galecto Inc (GLTO)'s fundamentals?

How many employees does Galecto Inc (GLTO). have?

Galecto Inc (GLTO) has 5 emplpoyees as of January 08 2026.

What is Galecto Inc (GLTO) market cap?

Today GLTO has the market capitalization of 33.54M USD.